MGC Pharma targeting EU + USSR + Asia with CannEpil
- The FDA last week approved UK-based GW Pharmaceuticals’ Epidiolex, a “pure plant-derived CBD” extract shown to drastically reduce seizures in children with epileptic syndromes.
- Marking the FDA’s first-ever approval of a cannabis-derived pharmaceutical product, the DEA has 90 days (until September 23) to schedule Epidiolex, a landmark decision being carefully scrutinized by the industry at large.
- Sales of Epidiolex will effectively open the pharmaceutical CBD market; the Hemp Business Journal (a division of New Frontier Data) forecasts the drug to generate between $15 million and $30 million in sales through 2018, and $180 million in 2019.
- HBJ expects the DEA to schedule Epidiolex as a Schedule IV drug and recommend that CBD be rescheduled from a Schedule I drug.
- Continued regulatory action by the FDA is expected against illicit claims and sales of unapproved, CBD-related products marketed with unproven medical claims.
- Forums
- ASX - By Stock
- RGT
- Hint of events to follow
Hint of events to follow, page-20
-
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGT (ASX) to my watchlist
(20min delay)
|
|||||
Last
36.0¢ |
Change
0.030(9.09%) |
Mkt cap ! $17.42M |
Open | High | Low | Value | Volume |
33.5¢ | 36.0¢ | 33.5¢ | $2.079K | 5.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 375 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 375 | 0.275 |
1 | 15000 | 0.260 |
1 | 20000 | 0.250 |
1 | 2200 | 0.230 |
1 | 4545 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 100 | 1 |
0.370 | 2000 | 1 |
0.380 | 1522 | 1 |
0.395 | 8746 | 1 |
0.400 | 1183 | 5 |
Last trade - 15.45pm 09/09/2024 (20 minute delay) ? |
Featured News
RGT (ASX) Chart |